In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy are two milestone achievements in clinical immunotherapy. However, both show limited efficacies in most solid neoplasms, which necessitates the exploration of new immunotherapeutic modalities. The failure of CAR-T and immune checkpoint blockade in several solid neoplasms is attributed to multiple factors, including low antigenicity of tumor cells, low infiltration of effector T cells, and diverse mechanisms of immunosuppression in the tumor microenvironment. New adoptive cell therapies have been attempted for solid neoplasms, including TCR-T, CAR-natural killer cells (CAR-NK), and CAR-macrophages (CAR-M). Compared to CAR-T, these new adoptive cell therapies have certain advantages in treating solid neoplasms. In this review, we summarized the 40-year evolution of adoptive cell therapies, then focused on the advances of TCR-T, CAR-NK, and CAR-M in solid neoplasms and discussed their potential clinical applications.

Brain-computer interfaces (BCIs) have shown great prospects as real-time bidirectional links between living brains and actuators. Artificial intelligence (AI), which can advance the analysis and decoding of neural activity, has turbocharged the field of BCIs. Over the past decade, a wide range of BCI applications with AI assistance have emerged. These "smart" BCIs including motor and sensory BCIs have shown notable clinical success, improved the quality of paralyzed patients' lives, expanded the athletic ability of common people and accelerated the evolution of robots and neurophysiological discoveries. However, despite technological improvements, challenges remain with regard to the long training periods, real-time feedback, and monitoring of BCIs. In this article, the authors review the current state of AI as applied to BCIs and describe advances in BCI applications, their challenges and where they could be headed in the future.

No abstract